Glenmark secures exclusive rights for Hansoh Pharma's Aumolertinib

Glenmark Specialty S.A. (GSSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd., announced an exclusive license, collaboration, and distribution agreement with Jiangsu Hansoh Pharmaceutical Group Co., Ltd. for Aumolertinib. This third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) is approved in the UK and China for the treatment of non-small cell lung cancer (NSCLC).

Under the agreement, Glenmark gains exclusive rights to develop and commercialize Aumolertinib across key territories including the Middle East, Africa, Southeast & South Asia, Australia, New Zealand, Russia/CIS, and select Caribbean countries. Hansoh Pharma will receive an upfront payment of low double-digit million USD, with potential regulatory and commercial milestone payments totaling over US$1 bn, in addition to tiered royalties on net sales.

Aumolertinib, marketed as Ameile in China and Aumseqa® in the UK and Europe, is indicated for first-line treatment of adult patients with locally advanced or metastatic NSCLC with activating EGFR mutations, and for EGFR T790M mutation-positive NSCLC. This strategic addition aligns with Glenmark's focus on expanding its innovative oncology portfolio.